Securities Claims In Drug Company Merger Deal Class Action Not Plausibly Pleaded

Mealey's (July 25, 2022, 2:11 PM EDT) -- PHILADELPHIA — A federal district court did not err in dismissing shareholder claims alleging that a commercial-stage biopharmaceutical company and its board of directors violated federal securities law by failing to...
To view the full article, register now.